Description
Understand the 340B Program and how the changes can affect multiple healthcare organizations.
The past few years have been an unusually tumultuous time in the 340B Program. This topic will outline the main challenges and opportunities for 340B Program stakeholders. The presenters will underline the practical steps that 340B Program stakeholders can take to ensure compliance and optimize 340B Program participation during the current shifting state of the 340B Program.
Date: 2024-04-18 Start Time: 1:00 PM ET End Time: 2:00 PM ET
Learning Objectives
* You will be able to review 340B background.
* You will be able to identify recent program changes.
* You will be able to discuss legislative updates.
* You will be able to recognize compliance problem areas and best practice strategies.
340B Program Background
• General Refresher on the 340B Program and Program History
• A High-Level Overview of Main 340B Program Requirements and Regulations
• Eligible Patient Definition Discussion
Recent Program Updates (Litigation)
• Update on the Current State of Manufacturer Restrictions and Appellate Court Review of Ongoing Litigation
• Update on Genesis Case and Impact on Eligible Patient Definition
• Potential Impact on Loper Supreme Court Case on 340B Program
Recent Program Updates (Legislative)
• Update on State-Level Contract Pharmacy Protection Laws
• Update on State-Level Pbm 340B Anti-Discrimination Laws
• Update on State and Federal 340B Transparency Initiatives
340B Optimization Strategies
• Alternative Distribution Models for Contract Pharmacy Arrangements
• Medication Therapy Management Clinics
• Referral Prescription Capture
ACHE ,CLE (Please check the Detailed Credit Information page for states that have already been approved) ,HFMA ,Additional credit may be available upon request. Contact Lorman at 866-352-9540 for further information.
Richard Davis, J.D.-Quarles & Brady LLP, Michael French, J.D. – Quarles & Brady LLP
